Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
CSL112 (apoA-I)'s own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for CSL112 (apoA-I). Showing past 6 months and next 12 months · 23 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| CSL112 (apoA-I) | CSL Limited | ApoA-I infusion (recombinant HDL) | Phase 3 | 0 | ||||
| ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS | Kyoto University, Graduate School of Medicine | Other |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI | Medical University of Gdansk | Small Molecule Other | Phase 4 | — | — | — | — | — |
| PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction | Kindai University | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome | Vastra Gotaland Region | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention | Fu Wai Hospital, Beijing, China | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Impact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome | King Edward Medical University | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) | J.P.S Henriques | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome | Punjab Institute of Cardology | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor | Collegium Medicum w Bydgoszczy | Microbiome Therapeutic | Phase 4 | — | — | — | — | — |
| Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention | Second Affiliated Hospital, School of Medicine, Zhejiang University | Other | Phase 4 | — | — | — | — | — |
| Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes | Shenyang Northern Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study | CHA University | Other | Phase 4 | — | — | — | — | — |
| IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome | Shanghai Zhongshan Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| CAPER-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS | West China Hospital | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction | University of Aarhus | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Small Molecule Other | Phase 4 | — | — | — | — | — |
| Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents | Odense University Hospital | Other | Phase 4 | — | — | — | — | — |
| Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol | Xiyuan Hospital of China Academy of Chinese Medical Sciences | Other | Phase 3 | — | — | — | — | — |
| Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Jiangsu vcare pharmaceutical technology co., LTD | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Novartis Pharmaceuticals | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | DalCor Pharmaceuticals | Small Molecule Other | Phase 3 | — | — | — | — | — |
| triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE | Heart Care Foundation | Small Molecule Other | Phase 3 | — | — | — | — | — |
| SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF | Region Örebro County | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty. | Cardiocentro Ticino | Small Molecule Other | Phase 3 | — | — | — | — | — |
| Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes | University of Sao Paulo | Small Molecule Other | PHASE2/PHASE3 | — | — | — | — | — |
| A Clinical Study of MT1002 in Subjects With Acute Coronary Syndrome Undergoing PCI | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO | IRCCS San Raffaele | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome | Pontificia Universidad Catolica de Chile | Small Molecule Other | Phase 2 | — | — | — | — | — |
| Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study | Yale University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Study Evaluating the Stability and Efficacy of IMC-001 for Injection on Atherosclerotic Plaques in Patients With ACS. | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Other | Phase 2 | — | — | — | — | — |
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Abcentra | Monoclonal antibody | Phase 2 | — | — | — | — | — |
| Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome | Yale University | Small Molecule Other | Phase 2 | — | — | — | — | — |
| A Polypill for Acute Coronary Syndrome | University of Texas Southwestern Medical Center | Small Molecule Other | Phase 2 | — | — | — | — | — |